Evidence map›Paper›PMID 33452979›Full record

ArticleBulletin of experimental biology and medicine2021

The Role of ESR1 Gene Polymorphic Markers in the Development of Breast Cancer and Resistance to Tamoxifen Therapy.

S S Lukina, A M Burdennyy, T M Zavarykina, D A Riabchikov, T P Kazubskaya, M P Kruglova, V I Loginov

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

S S LukinaResearch Institute of General Pathology and Pathophysiology, Moscow, Russia.
A M BurdennyyResearch Institute of General Pathology and Pathophysiology, Moscow, Russia. burdennyy@gmail.com.
T M ZavarykinaN. M. Emanuel Institute of Biochemical Physics, Russian Academy of Sciences, Moscow, Russia.
D A RiabchikovN. N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russian Federation, Moscow, Russia.
T P KazubskayaN. N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russian Federation, Moscow, Russia.
M P KruglovaI. M. Sechenov First Moscow State Medical University, Ministry of Health of Russian Federation (Sechenov University), Moscow, Russia.
V I LoginovResearch Institute of General Pathology and Pathophysiology, Moscow, Russia.
Research Institute of General Pathology and Pathophysiology, the Russian Academy of Medical Sciences · RUMinistry of Health of the Russian Federation · RUInstitute of Biochemical Physics NM Emanuel · RUSechenov University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We studied the effect of functionally significant polymorphic markers of the ESR1 gene on the risk of breast cancer, tamoxifen resistance, and survival of patients with this type of cancer. The study included 239 primary breast cancer patients without distant metastases. The analysis of genotype frequency distribution for the studied ESR1 gene polymorphic markers showed the association of the rs2228480 and rs2234693 markers with tamoxifen resistance in the group of patients with luminal B type breast cancer. An association of these two polymorphic markers with the risk of tumor development was also revealed; for rs2234693 polymorphic marker, a relationship with the survival of patients was also showed.

Indexed as

Antineoplastic Agents, HormonalBreast NeoplasmsDrug Resistance, NeoplasmEstrogen Receptor alphaFemaleGenotypeHumansTamoxifenAntineoplastic Agents, HormonalESR1 protein, humanEstrogen Receptor alphaTamoxifenbreast cancerdevelopmental riskESR1 genesurvivaltamoxifen

Identifiers

PMID33452979
OpenAlexW3125921068

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.